Summary
49 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 19 USD is left as net profit.
- The share price is below the Bulios Fair Price.
- Analysts expect revenue to grow by 16% this fiscal year.
What to watch
- Revenue fell by 36% a year over the last 3 years.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 29.7 USD for 1 USD of yearly profit. Over the last five years it was 31.5 USD on average.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue fell by 18% a year over 5 years. Over the last 3 years it fell by 36% a year. For the next fiscal year analysts expect revenue to grow by 16%. Earnings per share fell by 42% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 7.0 USD
- Research and development 43 USD
- Sales and administration 18 USD
- Taxes and other 13 USD
- Net profit 19 USD
Net profit, industry median (Biotechnology) -7.3 USD
Out of every 100 USD of revenue, 19 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 6.0 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 6
- Hold 3
- Sell 2
No analyst has published a price target.
55% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.